Global Experiences: Use of HTA for Health Benefit Packages Development, an ISPOR webinar
Health technology assessment (HTA) is increasingly used to inform universal health coverage (UHC), including financing and priority setting for benefit [...]
Real-world Evidence Put to the Test: Medicare’s New Codes for Remdesivir
The Centers for Medicare & Medicaid Services (CMS) has created new ICD-10-PCS procedure reimbursement codes to facilitate the generation of [...]
FDA Commissioner: COVID-19 Vaccine Must Adhere to Standards for Safety and Efficacy
Stephen Hahn, commissioner of the Food and Drug Administration penned an editorial in the August 5 issue of The Washington [...]
COVID-19 Vaccine Pricing: Are the Manufacturers Signaling their Intent?
The Wall Street Journal is reporting that vaccine manufacturers are signaling the price for coronavirus vaccines, with prices ranging from [...]
Patient Drug Costs Increased as Health Plans Promote Deductibles and Coinsurance, Says IQVIA Study
A decade ago, most patients were responsible for only their copay on a brand medication. However, the past few years [...]
Real-world Data Takes Center Stage in COVID-19 Response: Evidence Accelerator Community Tool Featured in Webinar by DIA
A webinar on "Real-World Data to Inform COVID-19 Response: Collaborating in the COVID-19 Evidence Accelerator" is taking place on Tuesday, [...]
RWE Challenges in Latin America featured in ISPOR Webinar on 10 August
The ISPOR Latin America Consortium Industry Committee is presenting a webinar "The Usage of Real-World Evidence (RWE): Monitoring and Managing [...]
Gilead Pricing of Remdesivir is “Immoral”, Says Pennsylvania’s Treasurer
Joe Torsella, Pennsylvania's elected treasurer, has come out swinging, calling Gilead Sciences "immoral" for their efforts to wring profit out [...]
Invoke a 1980’s Law to Lower Cost of Remdesivir for COVID-19, says 31 State Attorneys General
A coalition of attorneys general (AG) have requested the U.S. Department of Health and Human Services to invoke a federal [...]
Are You Making the Most of your Observational Data? How to Create a Synthetic Control from Your Natural History Study
In this blog from Cytel, a biostatistics and operations research provider, a case study is presented showing how real world [...]
Reminder: ICER webinar on Pricing in a Pandemic, Friday August 7
Session 3 in the ICER Colloquium Series entitled "Pricing in a Pandemic: Options, Debate, a Path Forward | Monetary Prizes, [...]
Trump’s “Buy American” Executive Order Could Raise Drug Prices
Tensions escalate with pharma as President Trump signs an executive order (EO) today directing the federal government to buy certain [...]
An OM1 Webinar: Exploring Best Practices and Innovation in the New Registry Handbook – 2 Part Series
First published in 2007, the AHRQ publication "Registries for Evaluating Patient Outcomes: A User's Guide" is among the most cited [...]
What is the Global Access Impact of COVID-19? DRG and Context Matters Weighs In
Mike Ward, Global Head of Thought Leadership at Decision Resources Group talks with Steve Edgar of DRG Global Market Access [...]
Virtual ISPOR-FDA Summit 2020 Program Announced | September 29
Virtual ISPOR-FDA Summit 2020, jointly sponsored by ISPOR and the US Food and Drug Administration (FDA) Center for Devices and [...]
Flatiron Health Collaborates with NICE on RWE for CEA
Flatiron Health, a healthcare technology company focused on cancer research and part of Roche, partnered with NICE to explore how [...]
CMS Issues Lowest Part D Premium Since 2013: AHIP Warns Rebate Rule Could Impact This
CMS has announced the average basic Part D premium for 2021 will be $30.50. This presents a slight uptick from [...]
Podcast: Will Patients See Lower Rx Prices, from Trump’s Executive Order?
The latest Patients Rising Podcast features Terry and Bob discussing policies such as co-pay accumulators and rebates, while Katy Talento [...]
The Cost Argument: Requiring Masks for COVID-19
Patients Rising, a national nonprofit organization dedicated to providing support and education to people with chronic and life-threatening illnesses, summarizes [...]
New Value & Outcomes Spotlight Editors Take the Helm
New Editors-in-Chief were recently appointed for Value & Outcomes Spotlight. Zeba M. Khan, RPh, PhD and Laura T. Pizzi, PharmD, [...]
ISPOR Europe 2020 Is Now Virtual | 14-18 November
Virtual ISPOR Europe 2020, “Improving Health: Establishing Incentives and Sharing Value,” will now be held as a completely virtual conference. [...]
ISPOR’s CSO Dr. Lucinda Orsini shares views on use of RWE by regulators and HTAs
In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics [...]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from [...]
A Digital Bridge To Real-Time COVID-19 Data
Several years ago, the Digital Bridge collaborative was formed, consisting of representatives from three key stakeholder communities: public health, the health care [...]
AMCP Introduces AMCP Collaborate online community to engage in discussions of managed care
AMCP, the organization for managed care pharmacists, today introduced AMCP Collaborate, an online community designed to give members a new platform to engage [...]